The latest report from the Make-an-IMPACT program focused on results delivered for pediatric cancer patients across 11 ...

The firm will use the funding to support a Phase I/II umbrella trial of three TCR T-cell candidates and its preclinical pipeline.

The firm plans to submit CMC data for DTX401 informed by the FDA's observations related to an application for its Sanfilippo syndrome type A gene therapy.

BUFFALO, New York – Five major research centers in New York have banded together to share resources and a manufacturing ...

At least 139 funded projects have focused on precision medicine since the council began awarding the grants in 2011, ...

If there are no dose-limiting toxicities, the company will test the CAR T-cell therapy at higher doses in more patients with FLT3-expressing refractory AML.

NEW YORK – Immunotherapy developer Xilio Therapeutics will showcase new masked T-cell engagers in its clinical pipeline over the next two years, the company said this week while announcing second ...

The Rare Therapies Launch Pad pilot aims to create a streamlined path to develop individualized treatments and get them approved.

The company will instead focus resources on its last remaining clinical asset, PRT7732, a chemically distinct SMARCA2 degrader.

The EMA's CHMP said the single pivotal US trial could serve as the basis for a marketing authorization application in the EU.